Latest

Advanced Liver Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

5 February 2026
DelveInsight’s, “Advanced Liver Cancer Pipeline Insight 2025” Report provides comprehensive insights about 50+ companies and 52+ pipeline drugs in Advanced liver cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Liver Cancer therapeutics assessment by
Bispecific-Antibody-Pipeline-Insights

Bispecific Antibody Pipeline Drugs and Companies Insight Report, 2025: Clinical, Commercial, and Developmental Analysis

4 February 2026
(Las Vegas, Nevada, United States) According to DelveInsight’s latest evaluation, the global bispecific antibody pipeline includes more than 180 active companies collectively developing over 250 bispecific antibody–based therapeutic candidates. The pipeline analysis provides a detailed overview of clinical trials, therapeutic approaches, mechanisms
Complicated-Urinary-Tract-Infection-Market-Insights

Complicated Urinary Tract Infection Market Forecast to 2034 Shows Strong Growth, Driven by Antibiotic Innovation and Rising Disease Burden

4 February 2026
The Complicated Urinary Tract Infection (cUTI) market is expected to witness substantial growth through 2034, supported by rising disease prevalence, increasing antimicrobial resistance (AMR), and a robust late-stage antibiotic pipeline, according to DelveInsight’s Complicated Urinary Tract Infection Market Insights, Epidemiology, and Forecast
Invasive-Aspergillosis-Market-Insights

Invasive Aspergillosis Market Outlook Signals Sustained Growth to 2034

4 February 2026
DelveInsight’s report titled “Invasive Aspergillosis Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive analysis of invasive aspergillosis, covering historical and projected epidemiology trends along with market dynamics across the United States, EU4 (Germany, France, Italy, and Spain), the United
1 2 3 4 5 13